Selepressin 1.25 ng/kg/minute (n = 10) | Selepressin 2.5 ng/kg/minute (n = 19) | Selepressin 3.75 ng/kg/minute (n = 2) | Placebo (n = 21) | |
---|---|---|---|---|
Demographics | ||||
Sex | ||||
Female/male, n (%) | 7 (70%)/3 (30%) | 9 (47%)/10 (53%) | 1 (50%)/1 (50%) | 6 (29%)/15 (71%) |
Age, years, mean (SD; median) | 59.3 (19.6–62.5) | 57.1 (15.4–59) | 69 (12.7–69) | 63.2 (18–66) |
Weight, kg, mean (SD; median) | 64.8 (14.3–63) | 87.6 (28.6–85) | 77.5 (17.7–78) | 75.1 (15.3–75) |
Total SOFA score, mean (SD; median) | 9.3 (2.2–9.5) | 11.2 (3.7–11) | 12 (0: 12) | 10.4 (3.5–11) |
Lactate, mEq/L, mean (SD) | 2.5 (1.5) | 3.0 (2.9) | 7.5 (8.1) | 2.5 (1.4) |
Mean arterial pressure, mmHg, mean (SD; median) | 66 (13–63) | 74 (9–70) | 69 (15–69) | 74 (13–69) |
Heart rate, beats/minute, mean (SD; median) | 90 (17–94) | 97 (20–91) | 110 (6–110) | 90 (20–93) |
Norepinephrine, μg/kg/minute, mean (SD) | 0.18 (0.09) | 0.28 (0.26) | 0.39 (0.20) | 0.34 (0.35) |
PaO2/FiO2, mean (SD; median) | 231 (108–200) | 257 (133–233) | 221 (24–221) | 246 (129–198) |
Primary infection type | ||||
Bacterial, n (%) | 7 (70%) | 14 (74%) | 2 (100%) | 15 (71%) |
Unknown, n (%) | 3 (30%) | 5 (26%) | 5 (24%) | |
Other, n (%) | 1 (5%) | |||
Primary infection location | ||||
Urinary tract, n (%) | 1 (10%) | 2 (11%) | 1 (5%) | |
Lung, n (%) | 1 (10%) | 6 (32%) | 1 (50%) | 8 (38%) |
Abdomen, n (%) | 4 (40%) | 8 (42%) | 9 (43%) | |
Unknown, n (%) | 2 (20%) | 1 (5%) | ||
Other, n (%) | 2 (20%) | 3 (16%) | 1 (50%) | 2 (10%) |
Main concomitant diseases | ||||
Gastrointestinal, n (%) | 8 (80%) | 14 (74%) | 1 (50%) | 20 (95%) |
Metabolic, n (%) | 6 60%) | 16 (84%) | 2 100%) | 18 (86%) |
Respiratory, n (%) | 7 (70%) | 12 (63%) | 2 100%) | 14 (67%) |
Renal, n (%) | 5 (50%) | 11 (58%) | 1 (50%) | 16 (76%) |
Subjects on mechanical ventilation | 4 (40%) | 11 (58%) | 0 | 15 (71%) |